Advancing Medicine. Precisely.

We have entered into a discovery collaboration with Janssen Pharmaceuticals, Inc. (see press release) utilizing our XMarker microbiome-based biomarker discovery platform to stratify responders and non-responders to inflammatory bowel disease (IBD) therapeutics. XMarker applies a unique metagenomics-based approach to decipher full microbial genomic signatures that can be further developed into predictive biomarkers.

Our collaboration with Boehringer Ingelheim (see press release) utilizes the BiomX XMarker microbiome-based biomarker discovery platform to potentially identify biomarkers associated with patient phenotypes in inflammatory bowel disease . The terms of the collaboration also include an option for Boehringer Ingelheim to negotiate an exclusive right to biomarkers discovered utilizing the XMarker platform.

We have entered into an agreement granting Maruho Co. Ltd., a leading dermatology-focused pharmaceutical company in Japan, a right of first offer to license our atopic dermatitis product candidate, BX005, in Japan. Maruho also entered into a binding agreement for an equity investment in the company, intended primarily to support the Phase 1/2 study of BX005